JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma

被引：0

作者：

Toshihiko Wakabayashi

Atsushi Natsume

Junki Mizusawa

Hiroshi Katayama

Haruhiko Fukuda

Minako Sumi

Ryo Nishikawa

Yoshitaka Narita

Yoshihiro Muragaki

Takashi Maruyama

Tamio Ito

Takaaki Beppu

Hideo Nakamura

Takamasa Kayama

Shinya Sato

Motoo Nagane

Kazuhiko Mishima

Yoko Nakasu

Kaoru Kurisu

Fumiyuki Yamasaki

Kazuhiko Sugiyama

Takanori Onishi

Yasuo Iwadate

Mizuhiko Terasaki

Hiroyuki Kobayashi

Akira Matsumura

Eiichi Ishikawa

Hikaru Sasaki

Akitake Mukasa

Takayuki Matsuo

Hirofumi Hirano

Toshihiro Kumabe

Nobusada Shinoura

Naoya Hashimoto

Tomokazu Aoki

Akio Asai

Tatsuya Abe

Atsuo Yoshino

Yoshiki Arakawa

Kenichiro Asano

Koji Yoshimoto

Soichiro Shibui

机构：

[1] Nagoya University Graduate School of Medicine,Department of Neurosurgery

[2] National Cancer Center Hospital,JCOG (Japan Clinical Oncology Group) Data Center/Operations Office

[3] Cancer Institute Hospital,Radiation Oncology Department

[4] Saitama Medical University International Medical Center,Department of Neuro

[5] National Cancer Center Hospital,Oncology/Neurosurgery

[6] Tokyo Women’s Medical University,Department of Neurosurgery and Neuro

[7] Nakamura Memorial Hospital,Oncology

[8] Iwate Medical University,Department of Neurosurgery

[9] Kumamoto University Graduate School of Medicine,Department of Neurosurgery

[10] Yamagata University Graduate School of Medicine,Department of Neurosurgery

[11] Kyorin University Faculty of Medicine,Department of Neurosurgery

[12] Shizuoka Cancer Center,Department of Neurosurgery

[13] Hiroshima University,Department of Neurosurgery

[14] Graduate School of Biomedical and Health Sciences,Department of Neurosurgery

[15] Hiroshima University Hospital,Department of Neurosurgery

[16] Ehime University Graduate School of Medicine,Department of Clinical Oncology & Neuro

[17] Chiba University Graduate School of Medicine,oncology Program

[18] Kurume University Graduate School of Medicine,Department of Neurosurgery

[19] Hokkaido University Graduate School of Medicine,Department of Neurosurgery

[20] University of Tsukuba,Department of Neurosurgery

[21] Keio University School of Medicine,Department of Neurosurgery

[22] The University of Tokyo Hospital,Department of Neurosurgery, Faculty of Medicine

[23] Nagasaki University Graduate School of Medicine,Department of Neurosurgery

[24] Kagoshima University Graduate School of Medical and Dental Sciences,Department of Neurosurgery

[25] Tohoku University Graduate School of Medicine,Department of Neurosurgery

[26] Kitasato University School of Medicine,Department of Neurosurgery

[27] Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital,Department of Neurosurgery

[28] Osaka University Graduate School of Medicine,Department of Neurosurgery

[29] Kitano Hospital,Department of Neurosurgery

[30] Kansai Medical University,Department of Neurosurgery

[31] Oita University Faculty of Medicine,Department of Neurosurgery

[32] Nihon University Graduate School of Medicine,Department of Neurosurgery

[33] Kyoto University Graduate School of Medicine,Department of Neurosurgery

[34] Hirosaki University Graduate School of Medicine,Department of Neurological Surgery

[35] Kyushu University,Department of Neurosurgery

来源：

Journal of Neuro-Oncology | 2018年 / 138卷

关键词：

Glioblastoma; Interferon-beta; Temozolomide; MGMT; RCT;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：627 / 636

页数：9

共 50 条

[31] Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
Grossman, Stuart A.
Ye, Xiaobu
Chamberlain, Marc
Mikkelsen, Tom
Batchelor, Tracy
Desideri, Serena
Piantadosi, Steven
Fisher, Joy
Fine, Howard A.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) : 4155 - 4161
[32] Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
Omuro, Antonio
Beal, Kathryn
Gutin, Philip
Karimi, Sasan
Correa, Denise D.
Kaley, Thomas J.
DeAngelis, Lisa M.
Chan, Timothy A.
Gavrilovic, Igor T.
Nolan, Craig
Hormigo, Adilia
Lassman, Andrew B.
Mellinghoff, Ingo
Grommes, Christian
Reiner, Anne S.
Panageas, Katherine S.
Baser, Raymond E.
Tabar, Viviane
Pentsova, Elena
Sanchez, Juan
Barradas-Panchal, Renata
Zhang, Jianan
Faivre, Geraldine
Brennan, Cameron W.
Abrey, Lauren E.
Huse, Jason T.
CLINICAL CANCER RESEARCH, 2014, 20 (19) : 5023 - 5031
[33] A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
Lee, Eudocia Q.
Kaley, Thomas J.
Duda, Dan G.
Schiff, David
Lassman, Andrew B.
Wong, Eric T.
Mikkelsen, Tom
Purow, Benjamin W.
Muzikansky, Alona
Ancukiewicz, Marek
Huse, Jason T.
Ramkissoon, Shakti
Drappatz, Jan
Norden, Andrew D.
Beroukhim, Rameen
Weiss, Stephanie E.
Alexander, Brian M.
McCluskey, Christine S.
Gerard, Mary
Smith, Katrina H.
Jain, Rakesh K.
Batchelor, Tracy T.
Ligon, Keith L.
Wen, Patrick Y.
CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3610 - 3618
[34] SAFETY ANALYSIS OF RANDOMIZED BELGIAN PHASE II TRIAL OF EXTENDED USE OF ADJUVANT TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS
Renard, L.
Clement, P. M.
Hammouch, F.
Boterberg, T.
Verschaeve, V.
Whenham, N.
Mitine, C.
Devriendt, D.
Baurain, J.
NEURO-ONCOLOGY, 2010, 12 : 46 - 47
[35] Randomized Phase II trial of Tumor Treating Fields plus radiation therapy plus temozolamide compared to radiation therapy plus temozolomide in patients with newly diagnosed glioblastoma
Grossman, Rachel
Limon, Dror
Bokstein, Felix
Ben Harosh, Carmit
Ram, Zvi
CANCER RESEARCH, 2019, 79 (13)
[36] Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
Clarke, Jennifer L.
Iwamoto, Fabio M.
Sul, Joohee
Panageas, Katherine
Lassman, Andrew B.
DeAngelis, Lisa M.
Hormigo, Adilia
Nolan, Craig P.
Gavrilovic, Igor
Karimi, Sasan
Abrey, Lauren E.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : 3861 - 3867
[37] Phase I/II study of pazopanib and temozolomide in patients with newly diagnosed and resected glioblastoma: Pazoglio trial.
Saada-Bouzid, Esma
Frenel, Jean-Sebastien
Augereau, Paule
Bourg, Veronique
Gal, Jocelyn
Jacquinot, Rique
Gourmelon, Carole
Chateau, Yann
Barriere, Jerome
Bondiau, Pierre-Yves
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[38] Phase 3 TRIDENT trial: Radiation and temozolomide plus /- Tumor Treating Fields in newly diagnosed glioblastoma
Glas, M.
STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S72 - S72
[39] A PHASE I STUDY OF AT-101 PLUS RADIOTHERAPY AND TEMOZOLOMIDE AND AT-101 PLUS ADJUVANT TEMOZOLOMIDE FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
Fiveash, John
Nabors, Louis B.
Mikkelsen, Tom
Peereboom, David M.
Lesser, Glenn J.
Chowdhary, Sajeel A.
Grossman, Stuart
Ye, Xiaubu
Leopold, Lance
Rosenfeld, Myrna
NEURO-ONCOLOGY, 2009, 11 (05) : 666 - 666
[40] Combination of temozolomide (TMZ) and radiotherapy (RT) versus radiotherapy (RT) alone in newly diagnosed glioblastoma multiforme (GBM): A randomized phase II study
Athanassiou, H
Synodinou, M
Maragoudakis, E
Paraskevaidis, M
Verigos, C
Misailidou, D
Antonadou, D
Sarris, G
Beroukas, K
Karageorgis, P
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S162 - S163

← 1 2 3 4 5 →